| CAS ID: | 100986-85-4 |
| Molecular Formula: | C18H20FN3O4 |
| Molecular Weight: | 361.4 g/mol |
| Monoisotopic Mass: | 361.1438 g/mol |
| Class: | Small Molecule |
| Natural Product: | No |
| Other Names: | DR-3355 | Floxacin | IQUIX | LEVAQUIN | TAVANIC | EVOXIL | RWJ-25213 | LEVOFLOXACIN | QUIXIN | OFTAQUIX | QUINSAIR |
| Analysis: | Drug repositioning mechanism analysis |
Reference Record 1
| PubMed ID | 19828274 | Target ID | |
| Uniprot ID | Name | ||
| Model | vitro | Fibrosis Disease | Cystic fibrosis |
| Process I | |||
| Process II | |||
| Process III | |||
| Mechanism | |||
Trial Record 1
| ClinicalTrial ID | NCT01180634 | Disease | Cystic fibrosis |
| Phase | Phase 3 | Status | Completed |
| First Received | August 12, 2010 | Last Verified | January 19, 2018 |
| Sponsor | Horizon Pharma USA, Inc. | ||
Trial Record 2
| ClinicalTrial ID | NCT00503490 | Disease | Cystic fibrosis |
| Phase | Phase 1 | Status | Completed |
| First Received | July 18, 2007 | Last Verified | January 19, 2018 |
| Sponsor | Horizon Pharma USA, Inc. | ||
Trial Record 3
| ClinicalTrial ID | NCT01270347 | Disease | Cystic fibrosis |
| Phase | Phase 3 | Status | Completed |
| First Received | January 5, 2011 | Last Verified | January 19, 2018 |
| Sponsor | Horizon Pharma USA, Inc. | ||
Trial Record 4
| ClinicalTrial ID | NCT00840333 | Disease | Cystic fibrosis |
| Phase | Phase 1 | Status | Completed |
| First Received | February 10, 2009 | Last Verified | January 19, 2018 |
| Sponsor | Horizon Pharma USA, Inc. | ||
Trial Record 5
| ClinicalTrial ID | NCT00677365 | Disease | Cystic fibrosis |
| Phase | Phase 2 | Status | Completed |
| First Received | May 14, 2008 | Last Verified | January 19, 2018 |
| Sponsor | Horizon Pharma USA, Inc. | ||